We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sequenom Selects PDI to Provide Sales Team for Launch of Noninvasive Prenatal Screening Tests

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Sequenom Selects PDI to Provide Sales Team for Launch of Noninvasive Prenatal Screening Tests"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:
PDI, Inc. and Sequenom Center for Molecular Medicine, LLC (SCMM) announced that PDI has been selected to provide the sales infrastructure to launch and commercialize SCMM's noninvasive prenatal genetic screening tests based on its SEQureDx™ technology.

Under the direction of SCMM management, PDI will support the commercialization of SCMM's fetal Rhesus D genotyping test from a maternal blood sample. This test will reduce the risk to the mother and fetus by providing clinicians early information.

Under the agreement, PDI will also provide sales support to SCMM upon commercialization of its noninvasive Down syndrome (Trisomy 21) test which is expected to be launched in June of this year, as well as other laboratory developed tests.

Under terms of the agreement, PDI in conjunction with the SCMM management team will hire, train and develop a sales team for the Sequenom Center for Molecular Medicine.

An initial wave of business development managers are targeted for the first quarter of 2009, with additional expansion scheduled throughout the second to fourth quarters of 2009. Sales call points will be focused on our obstetrician and perinatal specialist partners. Financial terms of the engagement were not disclosed.